References
- Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010; 103: 861-9. doi: 10.1038/sj.bjc.6605834
- Hao C, Cui Y, Owen S, Li W, Cheng S, Jiang WG. Human osteopontin: potential clinical applications in cancer (Review). Int J Mol Med 2017; 39: 1327-37. doi: 10.3892/ijmm.2017.2964
- Wei R, Wong JPC, Kwok HF. Osteopontin - a promising biomarker for cancer therapy. J Cancer 2017; 8: 2173-83. doi: 10.7150/jca.20480
- Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis 2018; 9: 356-70. doi: 10.1038/s41419-018-0391-6
- Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. Jama-Journal Am Med Assoc 2002; 287: 1671-9. doi: 10.1001/jama.287.13.1671
- Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011; 4: 365-74. doi: 10.1158/1940-6207.CAPR-10-0195
- Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 7677-82. doi: 10.1073/pnas.0502178102
- Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008; 14: 1065-72. doi: 10.1158/1078-0432.CCR-07-1569
- Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella T, et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 2004; 93: 361-5. doi: 10.1016/j.ygyno.2004.01.050
- Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004; 10: 3474-8. doi: 10.1158/1078-0432.CCR-03-0365
- Lan Z, Fu D, Yu X, Xi M. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis. Fam Cancer 2016; 15: 221-30. doi: 10.1007/s10689-015-9847-3
- Hu Z-D, Wei T-T, Yang M, Ma N, Tang Q-Q, Qin B-D, et al. Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review. PLoS One 2015; 10: e0126444. doi: 10.1371/journal.pone.0126444
- Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci 2007; 14: 373-81. doi: 10.1007/s11373-006-9143-1
- Psyrri A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A, et al. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. J Transl Med 2017; 15: 1-11. doi: 10.1186/s12967-017-1134-7
- Hacker NF. State of the art of surgery in advanced epithelial ovarian cancer. Ann Oncol 2013; 24: 27-32. doi: 10.1093/annonc/mdt465
- Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol 2016; 13: 255-61. doi: 10.1038/nrclinonc.2015.224
- Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, et al. European society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer 2017; 27: 1534-42. doi: 10.1097/IGC.0000000000001041
- Bristow RE, Karlan BY. Surgery for Ovarian Cancer: Principles and Practice 1st edition. Abingdon: Taylor & Francis; 2006.
- Chesnais M, Lecuru F, Mimouni M, Ngo C, Fauconnier A, Huchon C. A preoperative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer. PLoS One 2017; 12: 1-12. doi: 10.1371/journal.pone.0187245
- Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - A review of the epidemiological literature. J Ovarian Res 2009; 2: 1-20. doi: 10.1186/1757-2215-2-13
- Kobal B, Jerman KG, Karo J, Verdenik I, Cerne K. Relationship of ovarian cancer tumour markers concentration between local fluid and serum: Comparison of malignant to benign condition. Eur J Gynaecol Oncol 2018; 5: 743-50. doi: 10.12892/ejgo3848.2018
- Jerman KG, Kobal B, Jakimovska M, Verdenik I, Cerne K. Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy. World J Surg Oncol 2014; 12: 1-9. doi: 10.1186/1477-7819-12-278
- Lutz AM, Willmann JK, Cochran F V., Ray P, Gambhir SS. Cancer screening: A mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med 2008; 5: 1287-97. doi: 10.1371/journal.pmed.0050170
- Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg 1996; 83: 6-14. doi: 10.1002/BJS.1800830104
- Stanojevic Z, Rancic G, Radic S, Potic-Zecevic N, Djordjevic B, Markovic M, et al. Pathogenesis of malignant ascites in ovarian cancer patients. Arch Oncol 2004; 12: 115-8. doi: 10.2298/AOO0402115S
- Weber GF. The cancer biomarker osteopontin: Combination with other markers. Cancer Genomics Proteomics 2011; 8: 263-88. PMID: 22086896
- Bandiera E, Zanotti L, Fabricio ASC, Bucca E, Squarcina E, Romani C, et al. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelinrelated peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clin Chem Lab Med 2013; 51: 1815-24. doi: 10.1515/cclm-2013-0151
- Sato S, Itamochi H. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. Ther Adv Med Oncol 2014; 6: 293-304. doi: 10.1177/1758834014544891
- Skof E, Merlo S, Pilko G, Kobal B. The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer. Radiol Oncol 2016; 50: 341-6. doi: 10.1515/raon-2016-0034
- Rutten MJ, Leeflang MM, Kenter GG, Mol BW, Buist M. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database Syst Rev 2014; 21. doi: 10.1002/14651858.CD009786. pub2
- Cannistra SA. Cancer of the Ovary. N Engl J Med 1993; 329: 1550-9. doi: 10.1056/NEJM199311183292108
- Bookman MA, Ozols RF. Factoring outcomes in ovarian cancer. J Clin Oncol 1996; 14: 325-7. doi: 10.1200/JCO.1996.14.2.325
- Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000; 5: 26-35. doi: 10.1634/theoncologist.5-1-26
- Graessmann M, Berg B, Fuchs B, Klein A, Graessmann A. Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene 2007; 26: 2840-50. doi: 10.1038/sj.onc.1210096
- Hsieh I-S, Huang W-H, Liou H-C, Chuang W-J, Yang R-S, Fu W-M. Upregulation of drug transporter expression by osteopontin in prostate cancer cells. Mol Pharmacol 2013; 83: 968-77. doi: 10.1124/mol.112.082339
- Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, et al. Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer. Stem Cells Int 2015; 2015: 1-8. doi: 10.1155/2015/247892
- Zhang T, Zhang DM, Zhao D, Hou XM, Yang TN. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer. J BUON 2014; 19: 742-8. PMID: 25261661
- Luo S-D, Chen Y-J, Liu C-T, Rau K-M, Chen Y-C, Tsai H-T, et al. Osteopontin involves cisplatin resistance and poor prognosis in oral squamous cell carcinoma. Biomed Res Int 2015; 2015: 1-13. doi: 10.1155/2015/508587
- Faça VM, Ventura AP, Fitzgibbon MP, Pereira-Faça SR, Pitteri SJ, Green AE, et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One 2008; 3: e2425. doi: 10.1371/journal.pone.0002425